ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials.

Podobné jednotky

• The Effect of Recombinant Tissue Plasminogen Activator (r-tPA) on Quantitation of Neutralising Anti-Streptokinase Antibodies
  Autor: Afshin Afshari R. Elizbeth Holme
  Vydáno: (2004-09-01)
• PLASMINOGEN ACTIVATION BY LOW MOLECULAR WEIGHT STREPTOKINASE AND FIBRIN EFFECT
  Autor: E. I. Yusova
  Vydáno: (2014-06-01)
• Streptokinase versus recombinant tissue-type plasminogen activator for thrombolysis of mechanical prosthetic heart valve thrombosis
  Autor: Nilkanth Chandrakant Patil, a další
  Vydáno: (2016-01-01)
• The neurotoxicity of tissue plasminogen activator?
  Autor: Kaur, J, a další
  Vydáno: (2004)
• ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither
  Autor: Baigent, C, a další
  Vydáno: (1998)